This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Data Show That Women With Uterine Fibroids Experienced Significant And Long-Term Improvement In Their Symptoms With The Acessa™ Procedure

"The goal in developing the Acessa Procedure was to provide women with an option for effectively managing their fibroid symptoms while leaving their uterus intact, which isn't possible with some other procedures. We also wanted to minimize the impact that treatment would have on their lives," said Jeffrey M. Cohen, Halt Medical CEO. "The data presented at AAGL show that the same-day Acessa Procedure provides meaningful and lasting symptom control while leaving the uterus intact, minimizing the mental, physical and emotional impact of uterine fibroids on patients' daily lives."

In addition to managing fibroid symptoms and improving health related quality of life, treatment with Acessa also enables patients to rapidly return to normal life activities. In another study presented at AAGL, patients with uterine fibroids were randomized to receive treatment with standard surgery or the Acessa procedure. Data showed that those patients treated with standard surgery stayed three times longer in the hospital and were slower to return to regular activities than those patients who were treated with the Acessa Procedure.

The Halt Study Design The Halt Trial was designed to determine the efficacy and safety of radiofrequency volumetric thermal ablation (RFVTA) of symptomatic uterine fibroids in premenopausal women with symptomatic uterine fibroids and objectively confirmed heavy menstrual bleeding. Patients in this prospective, interventional clinical trial are women who had ≤ 6 treatable fibroids with no single fibroid exceeding 7 cm in any diameter, had a minimum of a three-month history of heavy menstrual bleeding within six months of enrollment, and desired uterine conservation. Outcome measures included: patient responses to validated questionnaires, treatment-emergent adverse events, and surgical re-intervention for fibroids at 24 months post-procedure. Comparisons between visits were based on t-tests using repeated measures models. Twelve- and 24-month outcomes from the Halt Trial have been reported in the literature. Data presented at AAGL analyze the clinical success of RFVTA of symptomatic uterine fibroids at two years of follow up.

About the Acessa Procedure The Acessa procedure is a minimally-invasive, same-day (outpatient) therapy for fibroids of all types and sizes, in all locations within and outside of the uterine wall. It uses a technology called radiofrequency volumetric thermal ablation. Each fibroid is destroyed by applying energy through a small needle array. The surrounding normal tissue is not affected. The destroyed tissue may then be completely reabsorbed and the uterus remains intact.

About Halt Medical, Inc. Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.

 

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs